Literature DB >> 3024615

Metabolic aspects of the development of experimental cardiac hypertrophy.

H G Zimmer, H Peffer.   

Abstract

In three models of cardiac hypertrophy the significance of catecholamines and the adenylate cyclase-cyclic AMP-system was examined. Two approaches were utilized: 1. The time course of cyclic AMP alterations was correlated with the changes in adenine nucleotide and protein biosynthesis. 2. The effect of beta-receptor blockade on the obligatory increase in adenine nucleotide and protein synthesis was evaluated. In isoproterenol-elicited cardiac hypertrophy, the elevation of the cyclic AMP content was one of the earliest metabolic alterations preceding the enhancement of the biosynthesis of adenine nucleotides and proteins. beta-Receptor blockade with propranolol abolished the increase in adenine nucleotide synthesis. In pressure-induced cardiac hypertrophy due to constriction of the abdominal aorta, catecholamines and the adenylate cyclase-cyclic AMP-system were found not to play a significant role. In triiodothyronine-elicited hypertrophy, the cyclic AMP level was increased very early, but beta-receptor blockade did not prevent hypertrophy nor the enhancement of cardiac adenine nucleotide biosynthesis, although the positive chronotropic and inotropic effects of triiodothyronine were abolished. This result can best be interpreted to indicate a direct effect of triiodothyronine on myocardial carbohydrate metabolism including the pentose phosphate pathway.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3024615     DOI: 10.1007/978-3-662-11374-5_13

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  16 in total

Review 1.  Regulation of protein turnover in skeletal and cardiac muscle.

Authors:  P H Sugden; S J Fuller
Journal:  Biochem J       Date:  1991-01-01       Impact factor: 3.857

2.  Catecholamines and cardiac growth.

Authors:  M P Gupta; M Gupta; S Jakovcic; R Zak
Journal:  Mol Cell Biochem       Date:  1996 Oct-Nov       Impact factor: 3.396

Review 3.  Regulation of and intervention into the oxidative pentose phosphate pathway and adenine nucleotide metabolism in the heart.

Authors:  H G Zimmer
Journal:  Mol Cell Biochem       Date:  1996 Jul-Aug       Impact factor: 3.396

4.  Energy metabolism and mechanical recovery after cardioplegia in moderately hypertrophied rats.

Authors:  R T Smolenski; J Jayakumar; A M Seymour; M H Yacoub
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

5.  Hyperthyroidism increases adenosine transport and metabolism in the rat heart.

Authors:  R T Smolenski; M H Yacoub; A M Seymour
Journal:  Mol Cell Biochem       Date:  1995-02-23       Impact factor: 3.396

6.  The oxidative pentose phosphate pathway in the heart: regulation, physiological significance, and clinical implications.

Authors:  H G Zimmer
Journal:  Basic Res Cardiol       Date:  1992 Jul-Aug       Impact factor: 17.165

7.  Function and energy metabolism of isolated hearts obtained from hyperthyroid spontaneously hypertensive rats (SHR). A 31P-nuclear magnetic resonance study.

Authors:  M Heckmann; S Lortet; J Aussedat; A Ray; A Rossi; H G Zimmer
Journal:  Mol Cell Biochem       Date:  1993-02-17       Impact factor: 3.396

8.  Reduction by oral propranolol treatment of left ventricular hypertrophy secondary to pressure-overload in the rat.

Authors:  I Ostman-Smith
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

9.  Right heart catheterization in rats with pulmonary hypertension and right ventricular hypertrophy.

Authors:  H G Zimmer; W Zierhut; R C Seesko; A E Varekamp
Journal:  Basic Res Cardiol       Date:  1988 Jan-Feb       Impact factor: 17.165

10.  Isoprenaline-induced increase in the 40/41 kDa pertussis toxin substrates and functional consequences on contractile response in rat heart.

Authors:  U Mende; T Eschenhagen; B Geertz; W Schmitz; H Scholz; J Schulte am Esch; R Sempell; M Steinfath
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-01       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.